
Jun 8, 2026 · 7 min
AI optimism and obesity breakthroughs lift Nvidia and Lilly
Nvidia Up, Campbell's Gains, Eli Lilly Rises as 30% Weight Loss Sets High Bar for Obesity Drug Race
The episode connects Nvidia’s confidence in expanding AI demand with Eli Lilly’s clinical progress and Campbell Soup’s changing market position.
- 1Jensen Huang says the AI buildout remains in its early stages, supporting Nvidia’s stock rise.
- 2Campbell Soup delivered mixed earnings as it prepares to leave the S&P 500.
- 3Eli Lilly posted clinical data showing its next-generation obesity drug achieved 30% weight loss.
Don't miss
Eli Lilly’s new clinical data showing 30% weight loss sets a demanding benchmark for competing obesity drugs.
The brief
Nvidia shares rose after CEO Jensen Huang reassured investors that the AI buildout is still in its early stages, reinforcing the case for continued technology spending.
The episode then turns to Campbell Soup, where mixed earnings arrive alongside the company’s upcoming exit from the S&P 500, a symbolic shift in market standing.
Eli Lilly provides the strongest pharmaceutical signal: new clinical data for its next-generation obesity drug points to 30% weight loss and raises expectations across the category.
Taken together, the stories show markets rewarding credible growth narratives while reassessing companies facing tougher benchmarks, weaker momentum, or changing investor status.
What was said on this episode
4 statements · 3 positive · 1 negative
Nvidia’s robotics roadmap aims to move robotics into industrial factories.
“the roadmap aims to be moving robotics from the research labs to actual factory floors”
Listen at 1:57
Eli Lilly’s next-generation obesity drug can produce 30% weight loss over two years.
“can help patients lose 30% of their body weight over about two years”
Listen at 3:48
Roche’s obesity drugs are less competitive on weight loss and have higher side effects.
“their drugs less competitive on weight loss and with higher side effects”
Listen at 3:58
Eli Lilly plans to shift obesity treatment toward more tailored customer needs.
“the years ahead, they're going to move from a one size fits all approach to something more tailored to customers needs”
Listen at 4:28
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.